Chicago, IL, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (“Xeris”), a specialty pharmaceutical company leveraging its novel te ...

Xeris announced that the Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its ready-to-use glucagon rescue pen for the treatment of severe hypoglycemia ...

Xeris Pharmaceuticals announced the completion of their two Phase 3 studies of an investigational ready-to-use rescue pen for the treatment of severe hypog Menu SECTIONS Home ...

In adults with long-standing type 1 diabetes experiencing mild to moderate hypoglycemia, treatment with a “mini-dose” of ready-to-use, subcutaneous glucagon is a safe, effective alternative to ...

Company announcement - No. 23/2017Zealand initiates first Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes ... Menu icon A vertical stack of three evenly spaced ...

As a result, the 150 μg dose was judged to be the optimal dose to treat mild hypoglycemia. As the G-Pen Mini glucagon unit is ready to use, the researchers believe this could be a valid treatment for ...

The U.S. Food and Drug Administration has approved Xeris Pharmaceuticals Inc's glucagon pen that aims to treat severely low sugar levels in diabetes patients, the drugmaker said on Tuesday. By ...

The US Food and Drug Administration has approved the first-ever generic glucagon injection kit for the treatment of severe hypoglycemia in patients with diabetes and as a diagnostic aid.. The FDA ...

Xeris Pharmaceuticals, Inc. (“Xeris”) recently announced successful completion of both adult and pediatric clinical studies for its glucagon rescue pen. According to Xeris’ President and CEO ...

At a minimum, I recommend that if a patient is on insulin, they should have a glucagon pen. Not only should the patient know how to use it, ... for the treatment of hypoglycemia, ...

Treatment . Hypoglycemia is treated using the 15-15 rule. ... susceptible to low blood sugar and should also talk with their doctor about carrying an emergency kit that contains a glucagon pen, ...

Xeris Pharmaceuticals, a late-stage pharma commercializing an injectable hypoglycemia treatment, filed on Thursday with the SEC to raise up to $75.